{"protocolSection":{"identificationModule":{"nctId":"NCT02928393","orgStudyIdInfo":{"id":"BP29937"},"secondaryIdInfos":[{"id":"2015-003227-66","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety, Efficacy and Pharmacodynamic Study of Basmisanil (RO5186582) in Adults With Severe Motor Impairment Following an Ischemic Stroke"},"statusModule":{"statusVerifiedDate":"2018-12","overallStatus":"TERMINATED","whyStopped":"Low participant enrolment","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-02-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-11-03","type":"ACTUAL"},"completionDateStruct":{"date":"2017-11-03","type":"ACTUAL"},"studyFirstSubmitDate":"2016-10-07","studyFirstSubmitQcDate":"2016-10-07","studyFirstPostDateStruct":{"date":"2016-10-10","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-12-28","lastUpdatePostDateStruct":{"date":"2019-01-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This Phase IIa, randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety, efficacy and pharmacodynamics of basmisanil in adult participants with severe motor impairment following an ischemic stroke."},"conditionsModule":{"conditions":["Stroke"],"keywords":["Stroke","Motor impairment","Stroke recovery","Middle cerebral artery stroke","Fugl Meyer","Fugl-Meyer Motor Scale (FMMS)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":5,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Basmisanil","type":"EXPERIMENTAL","description":"Basmisanil at a dose of 240 milligrams (mg) orally twice daily for 90 days.","interventionNames":["Drug: Basmisanil"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo matched to basmisanil orally twice daily for 90 days.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Basmisanil","description":"Basmisanil immediate-release granules at a dose of 240 mg will be given orally twice daily for 90 days.","armGroupLabels":["Basmisanil"],"otherNames":["RO5186582"]},{"type":"DRUG","name":"Placebo","description":"Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in FMMS Score at Day 90","timeFrame":"Baseline (Day 1), Day 90"},{"measure":"Number of Participants with Adverse Events","timeFrame":"Baseline (Day 1) up to 28 days after last dose of study drug (latest at Day 118)"},{"measure":"Change From Baseline in Montreal Cognitive Assessment (MoCA) Score at Day 30","timeFrame":"Baseline (Day 1), Day 30"},{"measure":"Change From Baseline in MoCA Score at Day 90","timeFrame":"Baseline (Day 1), Day 90"},{"measure":"Change From Baseline in National Institute of Health Stroke Scale (NIHSS) Score At Day 3","timeFrame":"Baseline (Day 1), Day 3"},{"measure":"Change From Baseline in NIHSS Score At Day 10","timeFrame":"Baseline (Day 1), Day 10"},{"measure":"Change From Baseline in NIHSS Score At Day 30","timeFrame":"Baseline (Day 1), Day 30"},{"measure":"Change From Baseline in NIHSS Score At Day 90","timeFrame":"Baseline (Day 1), Day 90"},{"measure":"Change From Baseline in NIHSS Score At 28 Days After Last Dose","timeFrame":"Baseline (Day 1) and at 28 days after last dose of study drug (latest on Day 118)"},{"measure":"Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) Score At Day 3","timeFrame":"Baseline (Day 1), Day 3"},{"measure":"Change From Baseline in C-SSRS Score At Day 30","timeFrame":"Baseline (Day 1), Day 30"},{"measure":"Change From Baseline in C-SSRS Score At Day 60","timeFrame":"Baseline (Day 1), Day 60"},{"measure":"Change From Baseline in C-SSRS Score At Day 90","timeFrame":"Baseline (Day 1), Day 90"},{"measure":"Change From Baseline in C-SSRS Score At 28 Days After Last Dose","timeFrame":"Baseline (Day 1), at 28 days after last dose of study drug (latest on Day 118)"}],"secondaryOutcomes":[{"measure":"Change From Baseline in Modified Rankin Scale (mRS) Score At Day 90","timeFrame":"Baseline (Day 1), Day 90"},{"measure":"mRS Score At Day 90","timeFrame":"Day 90"},{"measure":"Change From Baseline in Fugl-Meyer Assessment (FMA) Total Score at Day 90","timeFrame":"Baseline (Day 1), Day 90"},{"measure":"Change From Baseline in FMA Subscale Score at Day 90","timeFrame":"Baseline (Day 1), Day 90"},{"measure":"Apparent Oral Clearance (CL/F) of Basmisanil","timeFrame":"Predose (Hour 0) (prior to morning dose) on Days 3, 10, 30, 90; 4 and 8 hours post-morning dose on Day 1; and 4 hours post-morning dose on Day 3"},{"measure":"Maximum Observed Plasma Concentration (Cmax) of Basmisanil","timeFrame":"Predose (Hour 0) (prior to morning dose) on Days 3, 10, 30, 90; 4 and 8 hours post-morning dose on Day 1; and 4 hours post-morning dose on Day 3"},{"measure":"Apparent Volume of Distribution at Steady States (Vss) of Basmisanil","timeFrame":"Predose (Hour 0) (prior to morning dose) on Days 3, 10, 30, 90; 4 and 8 hours post-morning dose on Day 1; and 4 hours post-morning dose on Day 3"},{"measure":"Area Under the Curve [AUC] of Basmisanil","timeFrame":"Predose (Hour 0) (prior to morning dose) on Days 3, 10, 30, 90; 4 and 8 hours post-morning dose on Day 1; and 4 hours post-morning dose on Day 3"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Radiologic assessment confirming an acute middle cerebral artery ischemic stroke\n* Index stroke occurred within the past 3-4 days\n* Inpatient males and females\n* Severe hemiparesis or hemiplegia defined by FMMS score less than or equal to (\\</=) 35\n* Sufficient speech, vision and hearing to participate in study evaluations\n\nExclusion Criteria:\n\n* NIHSS greater than (\\>) 20\n* Severe aphasia that prevents a participant from following directions in rehabilitation\n* Significant deficit from prior strokes or pre-existing motor deficit\n* History of epilepsy, neurosurgery, severe head trauma or central nervous system infections that have residual symptomatology or have required treatment in the last 12 months\n* Known or suspected clinical seizure post-index stroke\n* History of pre-existing dementia or use of medications for dementia\n* History of clinically significant pre-existing psychiatric conditions within 12 months prior to stroke\n* Due to undergo carotid surgery within the next 4 months\n* Enrollment/participation in any interventional study (clinical trial) involving an investigational drug (unapproved) or non-drug treatment within the prior 3 months or 6 times the half-life (whichever is longer)\n* Clinically relevant medical conditions that would likely interfere with the study conduct and scheduled assessments\n* Contraindication to magnetic resonance imaging (MRI) or conditions which render interpretation of MRI difficult","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"CHU de Besancon Hopital Jean Minjoz; Service de Neurologie","city":"Besançon","zip":"25030","country":"France","geoPoint":{"lat":47.24878,"lon":6.01815}},{"facility":"Hôpital Pellegrin Tripode - CHU de Bordeaux","city":"Bordeaux","zip":"33076","country":"France","geoPoint":{"lat":44.84044,"lon":-0.5805}},{"facility":"Hopital la Cavale Blanche","city":"brest Cedex 2","zip":"29609","country":"France","geoPoint":{"lat":48.3903,"lon":-4.48628}},{"facility":"Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B","city":"Clermont-Ferrand","zip":"63003","country":"France","geoPoint":{"lat":45.77966,"lon":3.08628}},{"facility":"Hôpital General - Service de neurologie; Service de neurologie","city":"Dijon Cedex","zip":"21079","country":"France","geoPoint":{"lat":47.31667,"lon":5.01667}},{"facility":"Hopital Purpan","city":"Toulouse Cedex 9","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Hospital Universitario Puerta de Hierro","city":"Majadahonda","state":"Madrid","zip":"28222","country":"Spain","geoPoint":{"lat":40.47353,"lon":-3.87182}},{"facility":"Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia","city":"Barcelona","zip":"08025","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari Vall d'Hebron","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"La Paz University Hospital","city":"Madrid","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario Virgen Macarena","city":"Sevilla","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Virgen del Rocio","city":"Sevilla","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Clnico Universitario de Zaragoza","city":"Zaragoza","zip":"50009","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M21759","name":"Infarction, Middle Cerebral Artery","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":false}